The short version of preclinical research fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-16. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
=== Notable cases === 1994: Lucien Bouchard, future premier of Québec, Canada, who was infected while leader of the federal official opposition Bloc Québécois party, lost a leg to the illness. 1994: A cluster of cases occurred in Gloucestershire, in the west of England. Of five confirmed and one probable infection, two died. The cases were believed to be connected. The first two had acquired the Streptococcus pyogenes bacteria during surgery; the remaining four were community-acquired. The cases generated much newspaper coverage, with lurid headlines such as "Flesh Eating Bug Ate My Face". 1997: Jeff Moorad, former agent and partial owner of the San Diego Padres and Arizona Diamondbacks, contracted the disease. He had seven surgeries in a little more than a week and later fully recovered. 2004: Don Rickles, American stand-up comedian, actor, and author, known especially for his insult comedy, contracted the disease in his left leg. He had six operations and later recovered. The condition confined him in his later years to performing comedy from a chair. 2004: Eric Allin Cornell, winner of the 2001 Nobel Prize in Physics, lost his left arm and shoulder to the disease. 2005: Alexandru Marin, an experimental particle physicist, professor at MIT, Boston University, and Harvard University, and researcher at CERN and JINR, died from the disease. 2006: Alan Coren, British writer and satirist, announced in his Christmas column for The Times that his long absence as a columnist had been caused by his contracting the disease while on holiday in France. 2009: R. W.
Medieval thought experiments into the idea of a vacuum considered whether a vacuum was present, if only for an instant, between two flat plates when they were rapidly separated. There was much discussion of whether the air moved in quickly enough as the plates were separated, or, as Walter Burley postulated, whether a 'celestial agent' prevented the vacuum arising. Jean Buridan reported in the 14th century that teams of ten horses could not pull open bellows when the port was sealed.
Prince Harry becomes the first senior member of the British royal family to give evidence in a court case in more than 130 years when he appears at the High Court to give evidence in his case against Mirror Group Newspapers. The Advertising Standards Authority bans a 2022 campaign by Shell plc for being "likely to mislead" consumers. 7 June Figures produced by Halifax Bank indicate house prices have dropped by 1% compared to 2022, the first such fall since 2012. It is announced that The Daily Telegraph and Sunday Telegraph, as well as The Spectator, are to be put up for sale to recover debts incurred by the publications' parent company. 8 June Prime Minister Rishi Sunak holds a joint press conference with US president Joe Biden at the White House to announce the Atlantic Declaration, an agreement to strengthen economic ties between the UK and US. Caroline Lucas, the Green Party's former leader and only MP, announces that she is stepping down from Parliament at the next election. 9 June The UK government announces that the planned windfall tax on oil and gas companies will be suspended if prices return to normal levels for a sustained period. Nadine Dorries announces she will stand down as Conservative MP for Mid Bedfordshire with immediate effect, triggering a by-election. On 14 June 2023 she said that she had submitted a subject access request to the House of Lords Appointments Commission (HOLAC) and was waiting to resign until she had received all unredacted "WhatsApps, text messages, all emails and minutes of meetings" related to why she was denied a peerage.
1977: Argentine-Canadian scientist Veronica Dahl became the first graduate at Université d'Aix-Marseille II (and one of the first women in the world) to earn a PhD in artificial intelligence. 1977: Canadian-American Elizabeth Stern published her research on the link between birth control pills – which contained high levels of estrogen at the time – and the increased risk of cervical cancer development in women. Her data helped pressure the pharmaceutical industry into providing safer contraceptive pills with lower hormone doses. 1977: Janina Oszast is among the first Polish palaeobotanists attempting biogeographic synthesis of Miocene land sediments. She was also the first person in Poland to identify pollen from a range of herbaceous plants and the first to find pollen grains of Ephedra in glaciation period deposits. 1978: Anna Jane Harrison became the first female president of the American Chemical Society. 1978: American biochemist Mildred Cohn served as the first female president of the American Society for Biochemistry and Molecular Biology, then called the American Society of Biological Chemists.
Sources: en.wikipedia.org
== Prevention == As for the prevention of childhood malnutrition, there needs to be public health changes such as improving agriculture and improving access to healthcare to effectively reduce the rates of malnutrition in children. By educating individuals of childbearing age on proper nutrition and health during and after pregnancy, they can provide their children with the appropriate nutrients from a young age. By ensuring they are equipped with the proper education and resources, caretakers and infants are in better health, ultimately preventing childhood malnutrition. Because edema can hide decreased muscle mass, it can be hard to diagnose kwashiorkor in young children; however, if cases are overlooked, children become more susceptible to infections and can ultimately lead to morbidity and mortality. To prevent this from happening, parents can be educated on proper nutrition and the importance of breastfeeding infants to ensure they receive all the nutrients they need. A diet rich in carbohydrates, fats that provide at least 10% of the total caloric needs, and proteins that provide 15% of the caloric needs can prevent kwashiorkor. Proteins can be found in the following foods
In the BATT trial, growth velocity was decreased, bone age advancement was slowed, aggressiveness was decreased, and masculinization, measured via Tanner staging of pubic hair and genitals, did not appear to further progress. However, the decrease in growth rate was modest and fell just short of reaching statistical significance (p = 0.053). Conversely, although the decrease in rate of bone maturation was described as modest similarly, the ratio of bone age to chronological age was significantly reduced (p < 0.0001). Linear growth and skeletal maturation during normal puberty is mainly due to estradiol and not testosterone in both boys and girls, and hence inhibition of these processes with the combination of bicalutamide and anastrozole in precocious puberty would in theory be mostly dependent on the aromatase inhibitor rather than on bicalutamide. Testicular volume increased mildly over the year that the boys were observed. A New Drug Application of bicalutamide for FMPP in the United States was submitted on the basis of the BATT trial data. However, the application was not approved by the Food and Drug Administration, which cited insufficient evidence of effectiveness. Although indication of bicalutamide for the use was not granted, the bicalutamide medication label was updated to include the findings of the study. In terms of side effects, the combination of bicalutamide and anastrozole in the study was described as well tolerated with no safety concerns. However, gynecomastia, attributed to bicalutamide, was observed in almost half of the boys.
=== Changes that occur during the onset of gingivitis and periodontitis and its role in bleeding on probing === Following the infiltration of bacteria and its products within the sulcular epithelium, the inflammatory response triggers the release of matrix metalloproteinases which cause collagen destruction. Studies suggest that this mechanism is through the activation of Toll-Like Receptors (TLRs, such as TLR-9) which are present on epithelial cells upon binding with bacterial products (such as lipopolysaccharides, unmyelinated CpG motifs). The expression of these collagenolytic matrix metalloproteinases like MMP-13 and activated NF-κB subunit p65 (a type of transcription factor) was more commonly present in periodontitis tissue compared to gingivitis tissue, indicating that the extent of connective tissue destruction accelerates with the progression of the disease. As an effort to curb the incoming bacterial invasion, the basal cells of the sulcular epithelium, being triggered by the ongoing inflammation, proliferate in hopes to maintain an intact barrier against the bacteria and their products. Due to the ongoing inflammation, engorgement of vessels and vasodilation occurs at the underlying connective tissue of the sulcular epithelium. The concurrent destruction of the collagen will then result in the thinning or ulceration of the sulcular epithelium, making the engorged and more abundant blood capillaries more susceptible to rupture upon innocuous mechanical stimuli (such as those during toothbrushing, probing, flossing, eating).
== Interactions == TCTP is reported to interact with dozens of other proteins, which relates to its functions in many cellular and biological mechanisms. TCTP has been shown for example to interact with:
== Nomenclature == Accepted nomenclature is to designate the number of components of the rotaxane in brackets as a prefix. Therefore, the rotaxane consisting of a single dumbbell-shaped axial molecule with a single macrocycle around its shaft is called a [2]rotaxane, and two cyanostar molecules around the central phosphate group of dialkylphosphate is a [3]rotaxane.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.